Lebish, E.J.; Morgan, N.J.; Valentine, J.F.; Beswick, E.J.
MK2 Inhibitors as a Potential Crohn’s Disease Treatment Approach for Regulating MMP Expression, Cleavage of Checkpoint Molecules and T Cell Activity. Pharmaceuticals 2022, 15, 1508.
https://doi.org/10.3390/ph15121508
AMA Style
Lebish EJ, Morgan NJ, Valentine JF, Beswick EJ.
MK2 Inhibitors as a Potential Crohn’s Disease Treatment Approach for Regulating MMP Expression, Cleavage of Checkpoint Molecules and T Cell Activity. Pharmaceuticals. 2022; 15(12):1508.
https://doi.org/10.3390/ph15121508
Chicago/Turabian Style
Lebish, Eric J., Natalie J. Morgan, John F. Valentine, and Ellen J. Beswick.
2022. "MK2 Inhibitors as a Potential Crohn’s Disease Treatment Approach for Regulating MMP Expression, Cleavage of Checkpoint Molecules and T Cell Activity" Pharmaceuticals 15, no. 12: 1508.
https://doi.org/10.3390/ph15121508
APA Style
Lebish, E. J., Morgan, N. J., Valentine, J. F., & Beswick, E. J.
(2022). MK2 Inhibitors as a Potential Crohn’s Disease Treatment Approach for Regulating MMP Expression, Cleavage of Checkpoint Molecules and T Cell Activity. Pharmaceuticals, 15(12), 1508.
https://doi.org/10.3390/ph15121508